Review Article

Applicability of Isolates and Fractions of Plant Extracts in Murine Models in Type II Diabetes: A Systematic Review

Table 2

Biases analyses (ARRIVE) of the studies of the effects of fractions and isolates from the plants in the treatment of the type II diabetes.

IsolatesFractions
References Miura, et al., 2001 [26] Kavishankar and Lakshmidevi, 2014 [27] Moser et al., 2014 [28] Chen et al., 2009 [38] Ruan et al., 2012 [29] Sato et al., 2002 [30] Lo et al., 2006 [31] Yoshida et al., 2013 [32] Zhao et al., 2014 [34] Kumar et al., 2012 [40] Luo et al., 1999 [36] Perez-Gutierrez and Damian-Guzman, 2012 [35] Kwon et al., 2012 [37] Krenisky et al., 1999 [33] Hsu  et al., 2014 [39] Ren et al., 2015 [25] Agrawal et al., 2013 [42] Zhang et al., 2013 [41] Jeong and Song, 2011 [1] Chakrabarti et al., 2005 [44] Paramaguru et al., 2014 [43] Kiho et al., 2001 [45] Fujii et al., 2009 [46] Chen et al., 2013 [47] Arya et al., 2012 [49] Klomann et al., 2010 [48] Arya et al., 2012 [49] Xu et al., 2015 [17] Ibrahim and Islam, 2014 [50] Ganeshpurkar et al., 2014 [51] Shu et al., 2009 [52] Zhao et al., 2005 [54] Hwang et al., 2009 [55] Wu et al., 2005 [56] Xu et al., 2011 [57] Costantino et al., 2003 [58] Yu et al., 2015 [61] Kharbanda et al., 2014 [60] Roman-Ramos et al., 2012 [53]

Accurate and concise description of the content of the articleXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3384.62%

Abstract
Summary of the background, research objectives, methods, main findings, and conclusionsXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3692.30%

Introduction
Sufficient scientific backgroundXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3794.87%
Explanation of the experimental approach and rationaleXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3794.87%
Objectives
Clear primary and second objectivesXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3282.05%

Material and methods
Ethical statement
Nature of the ethical review permissions and institutional guidelines for the care and use of animalsXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3692.3%
Study design
Number of animals per groupXXXXXXXXXXXXXXXXXXXXXXXXXXXXX2974.35%
Information on whether the experiment was performed as a blind controlled studyXXXXXX615.38%
Experimental procedures
TreatmentXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX39100.00%
Dosage of treatmentXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3794.87%
Route of administrationXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3897.44%
Duration of treatmentXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3589.74%
Time of day for treatment administrationXXXXXXXXX923.07%
Location used for administration of treatmentX12.56%
Rationale for choice of specific dosageXXXXXXXXXXXX1230.76%
Rationale for choice of specific route of administrationXXXXXX615.38%
Experimental animals
Information on animal speciesXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3589.74%
Strain of the animalsXXXXXXXXXXXXXXXXXXXXXXXXXXXXX2974.36%
Sex of the animalsXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3692.30%
Animals weight rangeXXXXXXXXXXXXXXXXXXXXXX2256.41%
Age of the animalsXXXXXXXXXXXXXXXXXXXXXX2256.41%
Description of genetic modification status (knock-out, transgenic, and SPF)XXXXXXXXXXXXXXXXXX1846.15%
Information related to previous procedures performed on the animalsXXXXXXXXXXXXXXXXXXXXXXXXX2564.10%
Housing and husbandry
Housing of experimental animals (type of facility, type of cage or housing, material, and number of cage companions)XXXXXXXXXXXXXX1435.89%
Husbandry conditions (breeding programme, light/dark cycle, and temperature of water)XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3384.62%
Welfare-related assessments and interventions that were carried out before, during, or after the experimentXXXXX512.82%
Sample size
Total number of animals used in each experiment and the number of animals in each experimental groupXXXXXXXXXXXXXXXXXXXXXX2256.41%
Explanation regarding the decision of the number of animals and details of sample size calculationXX25.12%
Allocation of animals into experimental groups
Full details of how animals were allocated to experimental groups (including randomization or matching)XXXXXXXXXXX1128.20%
Order in which the animals in the different experimental groups were treated and assessedXXXXXXXXXXXXXXXXXXXXXXXXXXXX2871.79%
Experimental outcomes
Clear experimental outcomes assessedXXXXXXXXXXXXXXXXXXXXXXXXXXXX2871.79%
Statistical methods
Statistical methods used for each analysisXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3487.18%
Specification of the unit of analysis for each datasetXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3384.61%
Methods used to assess whether the data met the assumptions of the statistical approachXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3487.18%

Results
Baseline data
Description of the animals health status, for each experimental group, before treatmentXXXXXXXXXXXXXXXXXX1846.15%
Number analyzed
Number or animals in each group included in each analysis (absolute numbers)XXXXXXXXXXXX1230.76%
Animals or data not included in the analysis (and explanation for the exclusion)X12.56%
Outcomes and estimation
Information (mean = standard deviation)XXXXXXXXXXXXXXXXXXXX2051.28%
Information on quantification of inflammatory cells (mean = standard deviation)X12.56%
Adverse events
Information on mortality of experimental animal (mean = standard deviation)XXX37.69%
Modifications to the experimental protocols made to reduce adverse eventsXX25.12%
Discussion
Interpretation/scientific implications
Interpretation of the results, taking into account the study objectives and hypothesesXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX3589.74%
Comments on the study limitations (sources of bias and imprecision associated with the results)XXXXXXXXXXXX1230.76%
Generalizability /translation
Comments on how the findings are likely to translate to other species or systems (relevance to human biology)XXXXXXXXXXXXXXXXXXXXXX2256.41%
Funding
List of funding sources and the role of the funder(s) in the studyXXXXXXXXXXXXXXXXXXXXXXXXXXXX2871.79%

Results172831292415332628272325272320242124222729253227272729272822212532321617382630